ClinicalTrials.gg
CompletedNCT01224145Updated Nov 4, 2020Results posted

Assess the Feasibility and Efficacy of the CollaRx® Bupivacaine Implant Laparoscopic Inguinal or Umbilical Herniorrhaphy

A Phase 2 interventional study of 5x5cm bupivacaine collagen sponges in Hernia and Postoperative Pain, sponsored by Innocoll. Completed at 1 site in United States. Open to male participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2020-11-04.

Sponsored by Innocoll · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
10
Allocation
Not applicable
Ages
18 Years and older
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 12 studies testing bupivacaine in Hernia — 1 open to participants now, 1 under way, none of them phase 3. Bupivacaine · Hernia.

Enrollment
11th of 12
10 · median 89
Started
2011
the only one that year
Phase 2
3 of 12
none open now
Registered
3rd of 12
by date
Lead sponsor
2 of 12
Innocoll

Among the 12 studies testing bupivacaine in Hernia, this one is the 11th largest by enrollment, is the only one that started in 2011, is one of 3 in phase 2, and was the 3rd registered.

Hernia

257 studies on the registry are indexed under Hernia; 37 are open to participants now.

Browse Hernia studies →

Open to participants now

1 of the 12 studies testing bupivacaine in Hernia is open now. Recruiting first, the newest first:

Where they have run

About bupivacaine

Bupivacaine: first FDA approval 1972 (MARCAINE HYDROCHLORIDE PRESERVATIVE FREE), first EMA approval 2020. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 24 Hernia studies recruiting now, 17 (71%) set no upper age limit and 2 (8%) stop at 75 or younger; 4 take children under 18; 3 take healthy volunteers.

This study: 18 Years and older · male · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 12 studies testing bupivacaine in Hernia, or all of them as a file.
02

Study summary

This study will assess pain intensity for the first 72 hrs after aggravated movement (cough) following Laparoscopic Inguinal or Umbilical Herniorrhaphy.

Read the detailed description

Inguinal herniorrhaphy is a common surgery; approximately 2,800 per million people in the United States (US) undergo the procedure annually.Common surgical methods of herniorrhaphy include open and laparoscopic placement of synthetic mesh. Studies have shown that the use of synthetic mesh greatly reduces the risk of hernia recurrence regardless of the method used for its placement. Furthermore, utilizing the laparoscopic approach for umbilical hernia repair, specifically with the use of mesh, may also reduce the risk of infection.

Bupivacaine is a local anesthetic (pain medicine) that has an established safety profile. Collagen is a protein that is found in all mammals. The CollaRx Bupivacaine implant is a thin flat sponge made out of collagen that comes from cow tendons and contains bupivacaine. When inserted into a surgical site, the collagen breaks down and bupivacaine is released at the site but very little is absorbed into the blood stream. The high levels of bupivacaine at the surgical site may result in less pain for several days after surgery.

This open-label study will assess pain intensity after surgery in patients who receive the CollaRx Bupivacaine implant as well as determine the feasibility of the use of the laparoscope for sponge placement in laparoscopic hernia repair.

03

Conditions studied

  • Hernia
  • Postoperative Pain
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Male
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Man ≥18 years
  2. Has a planned unilateral inguinal herniorrhaphy (laparoscopy, transabdominal preperitoneal [TAPP] approach or totally extraperitoneal [TEP] approach) or laparoscopic umbilical herniorrhaphy to be performed according to standard surgical technique under general anesthesia.
  3. Willing to use opioid rescue analgesia.

Exclusion criteria

Exclusion Criteria:

  1. Has a known to amide local anesthetics, opioids, or bovine products.
  2. Scheduled for bilateral inguinal herniorrhaphy.
  3. Undergone a prior herniorrhaphy at the location scheduled for repair.
  4. Undergone major surgery within 3 months of the scheduled herniorrhaphy.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
10 participants (actual)

Study arms

  • Experimental
    Drug: Bupivacaine Collagen Sponge

    bupivacaine collagen sponges

    Drug: 5x5cm bupivacaine collagen sponges

Interventions

06

What researchers measure

Primary outcomes

  1. Total Use of Opioid Analgesia - Morphine Equivalence (mg)

    Dosages of 1 to 2 mg per dose were titrated to patient comfort according to institutional standards and at the investigator's discretion. Once patients could tolerate oral medication, they were offered oral morphine (15 mg tablets) as rescue analgesia if necessary. The dose for patients who weighed less than 75kg was 15mg every 3 to 4 hours as needed for pain control. The dose for patients who weighed 75kg or more was 1-2 tablets (15-30 mg) every 3-4 hours for pain control. Morphine was the preferred rescue medication.

    Time frame: 0 to 24 hours after surgery

  2. Total Use of Opioid Rescue Analgesia - Morphine Equivalence (mg)

    Dosages of 1 to 2 mg per dose were titrated to patient comfort according to institutional standards and at the investigator's discretion. Once patients could tolerate oral medication, they were offered oral morphine (15 mg tablets) as rescue analgesia if necessary. The dose for patients who weighed less than 75kg was 15mg every 3 to 4 hours as needed for pain control. The dose for patients who weighed 75kg or more was 1-2 tablets (15-30 mg) every 3-4 hours for pain control. Morphine was the preferred rescue medication.

    Time frame: 25-48 hours

  3. Total Use of Opioid Rescue Analgesia - Morphine Equivalence (mg)

    Dosages of 1 to 2 mg per dose were titrated to patient comfort according to institutional standards and at the investigator's discretion. Once patients could tolerate oral medication, they were offered oral morphine (15 mg tablets) as rescue analgesia if necessary. The dose for patients who weighed less than 75kg was 15mg every 3 to 4 hours as needed for pain control. The dose for patients who weighed 75kg or more was 1-2 tablets (15-30 mg) every 3-4 hours for pain control. Morphine was the preferred rescue medication.

    Time frame: 49-72 Hours

  4. Total Use of Opioid Rescue Analgesia Morphine Equivalence (mg)

    Dosages of 1 to 2 mg per dose were titrated to patient comfort according to institutional standards and at the investigator's discretion. Once patients could tolerate oral medication, they were offered oral morphine (15 mg tablets) as rescue analgesia if necessary. The dose for patients who weighed less than 75kg was 15mg every 3 to 4 hours as needed for pain control. The dose for patients who weighed 75kg or more was 1-2 tablets (15-30 mg) every 3-4 hours for pain control. Morphine was the preferred rescue medication.

    Time frame: 0-48 hours)

  5. Total Use of Opioid Rescue Analgesia - Morphine Equivalence (mg)

    Dosages of 1 to 2 mg per dose were titrated to patient comfort according to institutional standards and at the investigator's discretion. Once patients could tolerate oral medication, they were offered oral morphine (15 mg tablets) as rescue analgesia if necessary. The dose for patients who weighed less than 75kg was 15mg every 3 to 4 hours as needed for pain control. The dose for patients who weighed 75kg or more was 1-2 tablets (15-30 mg) every 3-4 hours for pain control. Morphine was the preferred rescue medication.

    Time frame: 0-72 hours

07

Results

Posted Nov 4, 2020

Participant flow

Participant flow — Overall Study
MilestoneDrug: Bupivacaine Collagen Sponge
Started10
Completed10
Not completed0

Outcome measures

PrimaryTotal Use of Opioid Analgesia - Morphine Equivalence (mg)

Dosages of 1 to 2 mg per dose were titrated to patient comfort according to institutional standards and at the investigator's discretion. Once patients could tolerate oral medication, they were offered oral morphine (15 mg tablets) as rescue analgesia if necessary. The dose for patients who weighed less than 75kg was 15mg every 3 to 4 hours as needed for pain control. The dose for patients who weighed 75kg or more was 1-2 tablets (15-30 mg) every 3-4 hours for pain control. Morphine was the preferred rescue medication.

Time frame:
0 to 24 hours after surgery
Reported as:
Mean · Morphine Equivalence (mg)
Total Use of Opioid Analgesia - Morphine Equivalence (mg)
Morphine Equivalence (mg)Bupivacaine Collagen Sponge
Total Use of Opioid Analgesia - Morphine Equivalence (mg)19.3 ± 15.5
PrimaryTotal Use of Opioid Rescue Analgesia - Morphine Equivalence (mg)

Dosages of 1 to 2 mg per dose were titrated to patient comfort according to institutional standards and at the investigator's discretion. Once patients could tolerate oral medication, they were offered oral morphine (15 mg tablets) as rescue analgesia if necessary. The dose for patients who weighed less than 75kg was 15mg every 3 to 4 hours as needed for pain control. The dose for patients who weighed 75kg or more was 1-2 tablets (15-30 mg) every 3-4 hours for pain control. Morphine was the preferred rescue medication.

Time frame:
25-48 hours
Reported as:
Mean · Morphine Equivalence (mg)
Total Use of Opioid Rescue Analgesia - Morphine Equivalence (mg)
Morphine Equivalence (mg)Bupivacaine Collagen Sponge
Total Use of Opioid Rescue Analgesia - Morphine Equivalence (mg)5.3 ± 7.3
PrimaryTotal Use of Opioid Rescue Analgesia - Morphine Equivalence (mg)

Dosages of 1 to 2 mg per dose were titrated to patient comfort according to institutional standards and at the investigator's discretion. Once patients could tolerate oral medication, they were offered oral morphine (15 mg tablets) as rescue analgesia if necessary. The dose for patients who weighed less than 75kg was 15mg every 3 to 4 hours as needed for pain control. The dose for patients who weighed 75kg or more was 1-2 tablets (15-30 mg) every 3-4 hours for pain control. Morphine was the preferred rescue medication.

Time frame:
49-72 Hours
Reported as:
Mean · Morphine Equivalence (mg)
Total Use of Opioid Rescue Analgesia - Morphine Equivalence (mg)
Morphine Equivalence (mg)Bupivacaine Collagen Sponge
Total Use of Opioid Rescue Analgesia - Morphine Equivalence (mg)2.0 ± 3.3
PrimaryTotal Use of Opioid Rescue Analgesia Morphine Equivalence (mg)

Dosages of 1 to 2 mg per dose were titrated to patient comfort according to institutional standards and at the investigator's discretion. Once patients could tolerate oral medication, they were offered oral morphine (15 mg tablets) as rescue analgesia if necessary. The dose for patients who weighed less than 75kg was 15mg every 3 to 4 hours as needed for pain control. The dose for patients who weighed 75kg or more was 1-2 tablets (15-30 mg) every 3-4 hours for pain control. Morphine was the preferred rescue medication.

Time frame:
0-48 hours)
Reported as:
Mean · Morphine Equivalence (mg)
Total Use of Opioid Rescue Analgesia Morphine Equivalence (mg)
Morphine Equivalence (mg)Bupivacaine Collagen Sponge
Total Use of Opioid Rescue Analgesia Morphine Equivalence (mg)24.6 ± 21.8
PrimaryTotal Use of Opioid Rescue Analgesia - Morphine Equivalence (mg)

Dosages of 1 to 2 mg per dose were titrated to patient comfort according to institutional standards and at the investigator's discretion. Once patients could tolerate oral medication, they were offered oral morphine (15 mg tablets) as rescue analgesia if necessary. The dose for patients who weighed less than 75kg was 15mg every 3 to 4 hours as needed for pain control. The dose for patients who weighed 75kg or more was 1-2 tablets (15-30 mg) every 3-4 hours for pain control. Morphine was the preferred rescue medication.

Time frame:
0-72 hours
Reported as:
Mean · Morphine Equivalence (mg)
Total Use of Opioid Rescue Analgesia - Morphine Equivalence (mg)
Morphine Equivalence (mg)Bupivacaine Collagen Sponge
Total Use of Opioid Rescue Analgesia - Morphine Equivalence (mg)26.6 ± 23.2

Adverse events

Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Drug: Bupivacaine Collagen Sponge0/10 (0%)1/10 (10%)8/10 (80%)
Most frequent serious events
Most frequent serious events
EventDrug: Bupivacaine Collagen Sponge
Sleep ApneaRespiratory, thoracic and mediastinal disorders1/10
Most frequent other events
Showing 10 of 14
Most frequent other events
EventDrug: Bupivacaine Collagen Sponge
HeadacheNervous system disorders2/10
NauseaGastrointestinal disorders2/10
HypoxemiaRespiratory, thoracic and mediastinal disorders2/10
ParesthesiaNervous system disorders1/10
ItchingSkin and subcutaneous tissue disorders1/10
ConstipationGastrointestinal disorders1/10
DiarrheaGastrointestinal disorders1/10
VomitingGastrointestinal disorders1/10
Scrotal SwellingReproductive system and breast disorders1/10
AnxietyPsychiatric disorders1/10

Baseline characteristics

Age, Continuous
Age, Continuous(years)Drug: Bupivacaine Collagen Sponge
Mean48 ± 9.76
Sex: Female, Male
Sex: Female, Male(Participants)Drug: Bupivacaine Collagen Sponge
Female0
Male10
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Drug: Bupivacaine Collagen Sponge
Hispanic or Latino4
Not Hispanic or Latino6
Unknown or Not Reported0
Region of Enrollment
Region of Enrollment(participants)Drug: Bupivacaine Collagen Sponge
United States10
08

Study locations

1 site
  • Research Concepts
    Bellaire, Texas, United States
09

References and documents

Publications

  • Hemsen L, Cusack SL, Minkowitz HS, Kuss ME. A feasibility study to investigate the use of a bupivacaine-collagen implant (XaraColl) for postoperative analgesia following laparoscopic surgery. J Pain Res. 2013;6:79-85. doi: 10.2147/JPR.S40158. Epub 2013 Feb 1. PubMed 23390367 ↗
10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Mar 2011 to primary completion in Jun 2011, 2 months.

Results were first posted in Nov 2020, 9 years 4 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 18, 2010
First posted
Oct 19, 2010
StartActual
Mar 22, 2011
Primary completionActual
Jun 20, 2011
CompletionActual
Jun 20, 2011
Results first posted
Nov 4, 2020
Last update
Nov 4, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 4, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01224145
Lead sponsor
Innocoll
Collaborators
Premier Research Group plc
Responsible party
Sponsor
First posted
Oct 19, 2010
Start date
Mar 22, 2011
Primary completion
Jun 20, 2011
Completion
Jun 20, 2011
Results posted
Nov 4, 2020
Last update
Nov 4, 2020

Study contacts

David Prior
study director · Innocoll

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Bupivacaine

Start the discussion